Press releases

Ghent and Marche-en-Famenne (Belgium), May 13^th, 2026 – ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company.

Marche-en-Famenne and Ghent, Belgium – June 10th, 2025 – ATB Therapeutics, a pioneering biopharmaceutical company specializing in innovative antibody-based therapies for oncology and immunology, is pleased to announce two major developments:
1. The appointment of Dr. Torsten Dreier as Chief Development Officer (CDO)
2. The opening of an additional research and development hub in Gent, Belgium

Belgium, 18 November 2024 – ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development. The Financing is co-led by EQT Life Sciences and MRL Ventures Fund (MRLV, corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA), alongside contributions from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and historical inverstors.